69 results
Page 2 of 4
8-K
EX-99.1
1a9d6z
27 Jul 23
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
6:00am
8-K
EX-99.1
18klrxs
28 Jun 23
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
6:02am
8-K
EX-99.1
xzx2n 6jsg
4 May 23
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:15pm
PRE 14A
9oihbh81mxm uph
17 Apr 23
Preliminary proxy
5:28pm
424B2
31v9g98c2dqmjrp
14 Apr 22
Prospectus for primary offering
5:13pm
424B5
hfe4l
12 Apr 22
Prospectus supplement for primary offering
5:25pm
8-K
EX-99.1
hy5 wc3rv13zb7h
17 Mar 22
Liquidia Corporation Reports Full-Year 2021
5:40pm